Nicotine therapeutic benefits: Difference between revisions

Line 510:

**Citation: McGrath, J., McDonald, J. W., & MacDonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004722.pub2

***Acknowledgements: Funding for the IBD/FBD Review Group (October 1, 2005 - September 30, 2010) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch; the Canadian Agency for Drugs and Technologies in Health (CADTH); and the CIHR Institutes of Health Services and Policy Research; Musculoskeletal Health and Arthritis; Gender and Health; Human Development, Child and Youth Health; Nutrition, Metabolism and Diabetes; and Infection and Immunity. Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.

===2002 [https://pubmed.ncbi.nlm.nih.gov/12072594/ Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice]===

*Animal Study

*Conclusions: (1) Two weeks of nicotine administration leads to contrasting effects on jejunal and colonic inflammation in IL-10 -/- mice. (2) Nicotine ameliorated inflammation in the colon, which was associated with enhanced expression of two protective peptides.

*[https://sci-hub.st/10.1097/00042737-200206000-00005 PDF of full paper]

**Citation: Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. Eur J Gastroenterol Hepatol. 2002 Jun;14(6):607-14. doi: 10.1097/00042737-200206000-00005. PMID: 12072594.

===1999 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/ Nicotine treatment for ulcerative colitis]===

@@ Line 510: / Line 510: @@
 **Citation: McGrath, J., McDonald, J. W., & MacDonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004722.pub2
 ***Acknowledgements: Funding for the IBD/FBD Review Group (October 1, 2005 - September 30, 2010) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch; the Canadian Agency for Drugs and Technologies in Health (CADTH); and the CIHR Institutes of Health Services and Policy Research; Musculoskeletal Health and Arthritis; Gender and Health; Human Development, Child and Youth Health; Nutrition, Metabolism and Diabetes; and Infection and Immunity. Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.
+===2002 [https://pubmed.ncbi.nlm.nih.gov/12072594/ Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice]===
+*Animal Study
+*Conclusions: (1) Two weeks of nicotine administration leads to contrasting effects on jejunal and colonic inflammation in IL-10 -/- mice. (2) Nicotine ameliorated inflammation in the colon, which was associated with enhanced expression of two protective peptides.
+*[https://sci-hub.st/10.1097/00042737-200206000-00005 PDF of full paper]
+**Citation: Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. Eur J Gastroenterol Hepatol. 2002 Jun;14(6):607-14. doi: 10.1097/00042737-200206000-00005. PMID: 12072594.
 ===1999 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/ Nicotine treatment for ulcerative colitis]===